CoChat
Sign Up
Cited by 214Retinal Diseases and TreatmentsRetinal Imaging and AnalysisOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials

Open access
Grunwald, Juan E., Pistilli, Maxwell, Daniel, Ebenezer, Ying, Gui-Shuang, Pan, Wei, Jaffe, Glenn J., Toth, Cynthia A., Hagstrom, Stephanie A., Maguire, Maureen G., Martin, Daniel F.·2017·Ophthalmology
DOI 10.1016/j.ophtha.2016.09.012PMC PMC5234734
Open this paper in CoChat — free account

Abstract

Purpose To estimate the incidence, size, and growth rate of geographic atrophy (GA) during 5 years of follow-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).Design Cohort within a clinical trial.Participants Participants included in CATT.Methods A total of 1185 CATT participants were randomly assigned to ranibizumab or bevacizumab treatment and to 3 treatment regimens. Participants were released from protocol treatment at 2 years and examined at approximately 5 years (N = 647). Two masked graders assessed the presence and size of GA in digital color photographs (CPs) and fluorescein angiograms (FAs) taken at baseline and years 1, 2, and 5. Cox proportional hazard models were used to identify risk factors for incidence of GA. Annual change in the square root of the total area of GA was the measure of growth. Multivariate linear mixed models including baseline demographic, treatment, and ocular characteristics on CP/FA and optical coherence tomography (OCT) as candidate risk factors were used to estimate adjusted growth rates, standard errors (SEs), and 95% confidence intervals (CIs).Main outcome measures Geographic atrophy incidence and growth rate.Results Among the 1011 participants who did not have GA at baseline and had follow-up images gradable for GA, the cumulative incidence was 12% at 1 year, 17% at 2 years, and 38% at 5 years. At baseline, older age, hypercholesterolemia, worse visual acuity, larger choroidal neovascularization (CNV) area, retinal angiomatous proliferation (RAP) lesion, GA in the fellow eye, and intraretinal fluid were associated with a higher risk of incident GA. Thicker subretinal tissue complex and presence of subretinal fluid were associated with less GA development. The overall GA growth rate was 0.33 mm/year (SE, 0.02 mm/year). Eyes treated with ranibizumab in the first 2 years of the clinical trial had a higher growth rate than eyes treated with bevacizumab (adjusted growth rate, 0.38 vs. 0.28 mm/year; P = 0.009). Geographic atrophy in the fellow eye, hemorrhage, and absence of sub-retinal pigment epithelium fluid at baseline were associated with a higher growth rate.Conclusions Development of GA is common 5 years after initiating therapy. Several risk factors identified at 2 years of follow-up persist at 5 years of follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2016.09.012

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 30 references

Cited by

Sorted by citations

Items 101–200 of 213

Related

See all

Metadata

Authors
Grunwald, J. E., Pistilli, M., Daniel, E., Ying, G.-S., Pan, W., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., Maguire, M. G., & Martin, D. F.
Affiliations
  • University of Pennsylvania (US)
  • Duke University (US)
  • Cleveland Clinic (US)
Corresponding author
Grunwald, Juan E.
ORCID
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2017-01
Volume
124
Issue
1
Pages
97-104
ISSN
0161-6420 (ISSN-L)
DOI
10.1016/j.ophtha.2016.09.012
PMC
PMC5234734
OpenAlex
W2545082692
Cited by
214
References
30
Citations by year
2026: 8 · 2025: 17 · 2024: 22 · 2023: 24 · 2022: 15 · 2021: 33 · 2020: 32 · 2019: 24 · 2018: 20 · 2017: 14
FWCI
21.24
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Eye Institute (U10EY017825, U10EY017826, R21EY023689, U10EY017823, U10EY023530, U10EY017828)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
geographic atrophy, age-related macular degeneration, incidence, ranibizumab, bevacizumab, choroidal neovascularization, retinal angiomatous proliferation, subretinal fluid, subretinal pigment epithelium, risk factors, anti-VEGF therapy, hemorrhage
MeSH terms
Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Female, Fluorescein Angiography, Humans, Macular Degeneration, Male, Middle Aged, Risk Factors, Incidence, Prevalence, Multivariate Analysis, Angiogenesis Inhibitors, Geographic Atrophy, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review